Prevention RFP

The Alzheimer's Drug Discovery Foundation's Prevention RFP backs work designed to delay or prevent Alzheimer's disease before symptoms progress. It is one of ADDF's core annual calls and sits alongside the foundation's biomarker and therapeutic routes, all of which reflect its mission-related investment model. The program uses grant funding and caps awards at $5 million. It is open globally to for-profit companies, nonprofits, universities, and research organizations, and the support is for direct costs only. ADDF runs the route on a letter-of-intent and invited full-proposal basis, which makes the review path more selective than an open rolling call. This route fits prevention studies with a clear development plan, especially those that can move toward human testing and trial execution. ADDF also requires all trials to register on ClinicalTrials.gov, so applicants need an organized regulatory and clinical framework. The strongest proposals are those that can show how prevention biology, trial design, and execution will line up in practice.

Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.